Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica Parasites
Top Cited Papers
Open Access
- 18 April 2006
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 3 (5) , e162
- https://doi.org/10.1371/journal.pmed.0030162
Abstract
Recent circumstantial evidence suggests that an increasing number of Iranian patients with cutaneous leishmaniasis are unresponsive to meglumine antimoniate (Glucantime), the first line of treatment in Iran. This study was designed to determine whether the clinical responses (healing, or non-healing) were correlated with the susceptibility of Leishmania parasites to Glucantime. In vitro susceptibility testing was first performed on 185 isolated parasites in the intracellular mouse peritoneal macrophage model. A strong correlation between the clinical outcome and the in vitro effective concentration 50% (EC50) values was observed. Parasites derived from patients with non-healing lesions had EC50 values at least 4-fold higher than parasites derived from lesions of healing patients. A selection of these strains was typed at the molecular level by pulsed-field gels and by sequencing the pteridine reductase 1 (PTR1) gene. These techniques indicated that 28 out of 31 selected strains were Leishmania tropica and that three were Leishmania major. The L. major isolates were part of a distinct pulsed-field group, and the L. tropica isolates could be classified in three related additional pulsed-field groups. For each pulsed-field karyotype, we selected sensitive and resistant parasites in which we transfected the firefly luciferase marker to assess further the in vitro susceptibility of field isolates in the monocyte cell line THP1. These determinations confirmed unequivocally that patients with non-healing lesions were infected with L. tropica parasites resistant to Glucantime. Additional characterization of the resistant isolates showed that resistance is stable and can be reversed by buthionine sulfoximine, an inhibitor of glutathione biosynthesis. To the authors' knowledge, this is the first report of proven resistant parasites contributing to treatment failure for cutaneous leishmaniasis and shows that primary Glucantime-resistant L. tropica field isolates are now frequent in Iran.Keywords
This publication has 58 references indexed in Scilit:
- Advances in leishmaniasisPublished by Elsevier ,2005
- Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral LeishmaniasisInfection and Immunity, 2005
- Clinical impact and relevance of antibiotic resistanceAdvanced Drug Delivery Reviews, 2005
- Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental modelsZeitschrift Fur Parasitenkunde-Parasitology Research, 2005
- Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1Biochemical Journal, 2004
- Characterization of the folylpolyglutamate synthetase gene and polyglutamylation of folates in the protozoan parasite LeishmaniaMolecular and Biochemical Parasitology, 2002
- DNA Transformation of Leishmania infantum Axenic Amastigotes and Their Use in Drug ScreeningAntimicrobial Agents and Chemotherapy, 2001
- Cutaneous leishmaniasis: Clinical aspectPublished by Elsevier ,1999
- High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion systemMolecular and Biochemical Parasitology, 1994
- Practical progress and new drugs for changing patterns of leishmaniasisParasitology Today, 1993